Article citationsMore>>

L. A. Lanza, A. L. Visbal, P. A. DeValeria, A. R. Zinsmeister, N. N. Diehl and V. F. Trastek, “Low-Dose Oral Amiodarone Prophylaxis Reduces Atrial Fibrillation after Pulmonary Resection,” The Annals of Thoracic Surgery, Vol. 75, No. 1, 2003, pp. 223-230. doi:10.1016/S0003-4975(02)04285-6

has been cited by the following article:

• TITLE: Diabetics Have the Same Risk and Benefits Regarding Postoperative Amiodarone Prophylaxis for Atrial Fibrillation When Undergoing Surgery for Lung Cancer

  AUTHORS: Lars P. Riber, Thomas D. Christensen, Hans K. Pilegaard

  KEYWORDS: Lung Surgery; Atrial Fibrillation; Diabetics

  JOURNAL NAME: Open Journal of Thoracic Surgery, Vol.3 No.2, June 5, 2013

  ABSTRACT: Background: To evaluate if the risk for developing atrial fibrillation after lung surgery is higher for diabetics than non-diabetic patients and whether diabetic status prolongs the length of in-hospital stay. Objective: To compare the outcome of amiodarone prophylaxis in diabetics and non-diabetics. Design: Subgroup analysis within a randomized, controlled, double-blinded trial. Results: Development of atrial fibrillation was equally frequent among diabetics (18.2%) and non-diabetics (20.5%) (p = 1.00). Atrial fibrillation occurred in 7.1% of prophylactic diabetics and in 9.3% of prophylactic non-diabetics, while 37.5% non-prophylactic diabetics and 31.3% non-prophylactic non-diabetics experienced atrial fibrillation (p = 0.31). Prophylactic amiodarone was equally effective in diabetics as in non-diabetics with a relative risk of 3.5 (1.8 - 67.0) and the number need to treat of 4.4 (3.3 - 8.3) (p = 0.31). The length of in-hospital stay for diabetics was equal to non-diabetics with an average stay of 7.1 versus 8 days at Aarhus University Hospital (p = 0.61) with similar stays at intermediary and intensive care unit as well as total in-hospital stay of 8.9 versus 10 days (p = 0.60). Conclusions: Diabetics have the same risk of atrial fibrillation and the same benefits from prophylactic amiodarone as non-diabetics after surgery for lung cancer. Furthermore, diabetics have the same length of stay as non-diabetics. No severe adverse effects were found in either group.